We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Senate Finance Committee is scheduled to hold a hearing today on the nomination of FDA Commissioner Mark McClellan to head the Centers for Medicare & Medicaid Services, under an agreement reached last week by Committee Chairman Chuck Grassley (R-Iowa) and ranking committee Democrat Sen. Max Baucus (D-Mont.).
The Republican chairman and the ranking Democrat on the House Government Reform Committee have introduced legislation designed to curb the growing number of Rx drugs sold over the internet without a valid prescription.
Irritated that a previous request for information on Medicare cost estimates has not been answered, several House members yesterday fired off another letter to HHS Secretary Tommy Thompson and invoked the little-known "Seven-Member Rule," demanding that the secretary supply the information by March 15.
Senate Finance Committee Chairman Chuck Grassley (R-Iowa) and ranking committee Democrat Sen. Max Baucus (D-Mont.) have agreed to approve the nomination of FDA Commissioner Mark McClellan as head of the Centers for Medicare & Medicaid Services.
Senate supporters of the reimportation of prescription drugs quietly introduced a bill last week that would allow imports from 25 industrialized countries, effectively bypassing a certain committee roadblock in favor of what they consider better odds of passage on the Senate floor.
Pharmaceutical manufacturers yesterday denied they will reap billions of dollars in additional profits under the new Medicare prescription drug law, saying the benefit will have little overall effect on revenues or research and development efforts.
The chairman of the Senate Committee on Finance is demanding a clarification from the Centers for Medicare and Medicaid Services (CMS) on the criteria used for assessing patient’s needs for motorized wheelchairs.
A bipartisan group of senators is threatening to block the confirmation of FDA Commissioner Mark McClellan as head of the Centers for Medicare & Medicaid Services (CMS) unless he answers questions about the FDA’s opposition to the reimportation of drugs.
Rep. James Greenwood (R-Pa.) is searching back five years for evidence that drugmakers obtained undue influence over grant approvals and other decisions at the National Institutes of Health (NIH) by hiring NIH scientists as consultants.
The White House’s official revelation of one of the worst kept secrets in Washington — that FDA Commissioner Mark McClellan is President Bush’s selection to take over at the Centers for Medicare & Medicaid Services (CMS) — has triggered a shuffling of leadership roles at the FDA.